Page last updated: 2024-09-04

canertinib and sb 202190

canertinib has been researched along with sb 202190 in 3 studies

Compound Research Comparison

Studies
(canertinib)
Trials
(canertinib)
Recent Studies (post-2010)
(canertinib)
Studies
(sb 202190)
Trials
(sb 202190)
Recent Studies (post-2010) (sb 202190)
1249656510202

Protein Interaction Comparison

ProteinTaxonomycanertinib (IC50)sb 202190 (IC50)
Mitogen-activated protein kinase 13Homo sapiens (human)0.08
Bromodomain-containing protein 4Homo sapiens (human)2.95
TyrosinaseMus musculus (house mouse)0.03
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)0.08
Casein kinase I isoform deltaHomo sapiens (human)0.188
Mitogen-activated protein kinase 12Homo sapiens (human)0.08
Mitogen-activated protein kinase 11Homo sapiens (human)0.1038
Mitogen-activated protein kinase 14Homo sapiens (human)0.0625
Tau-tubulin kinase 2Homo sapiens (human)9.34
large T antigenBetapolyomavirus macacae4.87

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; LĂ©lias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP1
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1

Other Studies

3 other study(ies) available for canertinib and sb 202190

ArticleYear
A small molecule-kinase interaction map for clinical kinase inhibitors.
    Nature biotechnology, 2005, Volume: 23, Issue:3

    Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines

2005
A quantitative analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2008, Volume: 26, Issue:1

    Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship

2008
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013